Zhu, Chen, Xie, and Sun et al. demonstrated that the ACSS2-KAT2A interaction blocking peptide, when combined with anti-PD-1 antibodies, exerts superior tumor-suppressive effects. Here, ACSS2 is linked to neoplasm.